Skip to content
The Policy VaultThe Policy Vault

Brukinsa (zanubrutinib) — Highmark

Marginal Zone Lymphoma (MZL)

Initial criteria

  • age ≥ 18 years
  • diagnosis of relapsed or refractory MZL (ICD-10 C88)
  • received at least one previous anti-CD20-based regimen